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As healthcare costs in the United States continue to rise, healthcare providers 
must do their part to negate the expenses incurred by hospitals and patients. However, 
some treatments or medications may be more beneficial than others but come at a higher 
price. Such is the case with sugammadex, a medication approved for use in 2015 that can 
effectively and reliably reverse paralysis brought about by aminosteroidal induced 
neuromuscular blockade with rocuronium. Neostigmine/robinul combinations have 
traditionally been used for neuromuscular blockade reversal but with less efficient results 
than sugammadex (Abad-Gurumeta et al., 2015). Hence, a cost analysis was conducted at 
a facility in North Mississippi with a 9-bed operating room to compare the price 
difference between these two methods of reversing neuromuscular blockade. After prices 
for each medication were retrieved from the facility, a mean number of cases requiring 
neuromuscular blockade for surgery was calculated per month. The cost of sugammadex 
was applied to the average case number and then added over a 6-month period. The same 
was also done for the neostigmine/robinul combination. The calculation resulted in 
sugammadex totaling $63,416.64 over six months and neostigmine/robinul combination 
totaling $12,485.76 over six months. A difference of $50,930.88, which results in 80.3% 
cost-savings, was noted between the two reversal methods in favor of 
neostigmine/robinul. The results were shared with anesthesia providers at the facility 
along with an extensive literature review describing the benefits and complications of 
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CHAPTER I - INTRODUCTION 
Healthcare expenditure in the United States has increased steadily over the years 
and is currently projected to increase further (Centers for Medicare and Medicaid 
Services [CMS], 2016). The cost is expected to increase to as much as $5.7 trillion by the 
year 2026, consuming 19.7% of the gross domestic product of the United States (CMS, 
2016). Costs in 2016 were estimated at $3.3 trillion with $328.6 billion (10%) owed to 
drug costs (CMS, 2016). Efforts are being made nationwide to decrease these costs while 
simultaneously providing high-quality health care to those in need. 
These efforts extend into the operating room, where competent anesthesia 
providers must balance costs, risks, and benefits of any drug to be administered to a 
patient. Some of the drugs used in anesthesia practice accomplish similar goals. 
However, the drugs can vary in price and also affect the operating room (OR) time, post-
anesthesia care unit (PACU) time, and the general wellness of the patient. All of these 
variables can increase or decrease the cost of health care and must often be weighed 
together to provide the most cost-effective, high-quality care that can be afforded. 
Sugammadex was approved in 2015 as an alternative neuromuscular blocker 
(NMB) reversal agent.  Anesthesia providers have deliberated Sugammadex’s cost 
against the traditional use of other reversal agents. However, costs can differ greatly for 
NMB reversal agents from institution to institution. Identifying the actual difference in 
price between NMB reversal agents when deliberating about their use is prudent. 
Background and Significance 
Different classes of NMBs exist with respect to how they work and how they are 
metabolized. Commonly used paralytics include rocuronium and vecuronium, 
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intermediate-acting aminosteroidal NMBs, and cisatracurium, an intermediate-acting 
benzylisoquinolone. Benzylisoquinolones are eliminated by the pH and temperature of 
the body and reversed with NMB reversal agents (Carron, Baratto, Zarantonello, & Ori, 
2016). Aminosteroidal NMBs, like rocuronium, must either be metabolized and excreted 
over time or antagonized with reversal medications (Carron et al., 2016). 
Neostigmine and robinul combinations are hallmark medications used by 
anesthesia providers to reverse neuromuscular blockade. Sugammadex was recently 
approved in 2015 by the U.S. Food and Drug Administration (FDA) and provides a rapid 
and reliable alternative to neostigmine/robinul for rocuronium NMB reversal (Cada, 
Levien, & Baker, 2016). Abad Gurumeta et al. (2015) state that sugammadex was 
associated with a significantly lower incidence of side effects and postoperative residual 
curarization (PORC) when compared with neostigmine for NMB reversal. However, 
concerns over the cost of sugammadex, as compared to neostigmine/robinul, have limited 
its use among anesthesia providers. 
PICO/Project Question 
Is a full dose neostigmine/robinul NMB reversal more cost-effective than full 
dose sugammadex reversal for neuromuscular blockade when evaluated by cost analysis? 
The cost of a full dose reversal of rocuronium with neostigmine/robinul will be compared 
to a full dose reversal with sugammadex to assess the estimated costs of both. The known 
benefits and complications of sugammadex and neostigmine/robinul will be discussed 




Healthcare professionals all have a shared responsibility to decrease costs in the 
United States. Therefore, anesthesia providers must do their part in selecting medications 
that will benefit the patient to the greatest degree within financially reasonable means. 
NMB reversal agents are no different in this aspect. 
Sugammadex has been proven effective in minimizing complications, hastening 
recovery, and having fewer side effects in comparison with neostigmine/robinul (Abad-
Gurumeta et al., 2015; Carron et al., 2016; Chambers et al. 2010; Ledowski et al., 2012; 
Unal et al., 2015). The cost has been the factor limiting the use of sugammadex in many 
institutions. Ledowski et al. (2010) confirmed cost as the limiting factor in their study 
after prices were negotiated at Royal Perth Hospital in Australia. 
However, sugammadex and neostigmine/robinul prices can vary in different 
regions depending on how the drugs are purchased. Rebates, discounts, group purchasing 
organizations (GPOs), average wholesale prices (AWPs), manufacturer costs, and other 
factors make labeling one drug with a specific price difficult (Mattingly, 2012). 
Understanding these terms and how they are used can aid the anesthesia provider in 
choosing the most appropriate NMB reversal agent. 
Purpose of the Project 
The project purpose was to establish the cost efficiency of full dose sugammadex 
in comparison with full dose neostigmine/robinul for NMB reversal at a single facility. 
The results were shared with the anesthesia staff at the facility. Disseminating the results 





The needs assessment was established after a discussion with the chief certified 
registered nurse anesthetist (CRNA) at a hospital in north Mississippi. Questions had 
been raised by the anesthesia staff over the cost of sugammadex versus 
neostigmine/robinul for NMB reversal. The CRNA requested that a cost analysis be 
conducted to evaluate the cost-efficiency of sugammadex compared to the traditional use 
of neostigmine/robinul at the facility. 
Conceptual Framework 
The Donabedian Model was utilized as the framework for this project. 
Donabedian’s model is the most commonly used theoretical framework among health 
services research (Ancker et al., 2012). The Donabedian model evaluates healthcare 
quality by dividing the systems approach into three groups. These divisions are structure, 
processes, and outcomes.  
The structure includes the organizational, material, and human resources that exist 
within the health care system (Ancker et al., 2012). These components of structure 
greatly influence the quality of care given. The anesthesia personnel and pharmacy at the 
health care facility were the structure for this project. 
Processes are actions carried out by the system and personnel within it (Ancker et 
al., 2012). Therefore, selection of the NMB reversal agent by the anesthesia provider is 
the most prominent action applicable to this project. Pharmacy purchasing options also 
influence the cost. 
Lastly, outcomes refer to the end result that can be measured or quantified in 
some way (Ancker et al., 2012). The outcome assessed refers to the difference in cost of 
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full dose reversal of NMB with sugammadex as opposed to neostigmine/robinul. Benefits 
were established by means of a literature review, to aid in the selection of the appropriate 
NMB reversal agent. 
DNP Essentials 
The American Association of Colleges of Nursing (AACN) has established eight 
essentials necessary for DNP graduates to prove competent in for credentialing purposes 
(AACN, 2006). The eight essentials are complemented by actions performed during the 
project as follows: 
• Essential I, Scientific Underpinnings for Practice, was performed by conducting a 
literature review of the cost, benefits, and risks of both sugammadex and 
neostigmine/robinul. 
• Essential II, Organizational and Systems Leadership for Quality Improvement and 
Systems Thinking, was performed by establishing the cost efficiency of full dose 
reversal of NMB with sugammadex versus neostigmine/robinul and presenting 
evidence of the benefits and risks of each. 
• Essential III, Clinical Scholarship and Analytical Methods for Evidence-Based  
Practice was performed by applying information gathered from the literature 
review and creating an analyzed cost comparison between NMB reversal agents. 
• Essential IV, Information Systems/Technology and Patient Care Technology for  
the Improvement and Transformation of Health Care were performed by 
conducting a literature review using information databases and accessing hospital 
resources for cost estimation. 
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• Essential V, Health Care Policy for Advocacy in Health Care, was performed by 
forming results and presenting the results with anesthesia staff at the health care 
facility to improve health care delivery. 
• Essential VI, Inter-professional Collaboration for Improving Patient and  
Population Health Outcomes was performed by interacting with anesthesia staff at 
the healthcare facility regarding cost efficiency of NMB reversal selection and 
known risks and benefits of each type. 
• Essential VII, Clinical Prevention and Population Health for Improving the  
Nation’s Health was performed by reviewing current literature regarding benefits 
and risks of NMB agents as it relates to cost efficiency so safe, quality health care 
delivery can be given. 
• Essential VIII, Advanced Nursing Practice, was performed by presenting results 
of the cost efficiency analysis of sugammadex versus neostigmine/robinul to the 
CRNAs with respect to the benefits and risks provided by current literature. 
Review of the Evidence 
The literature review was conducted via electronic databases including the Cumulative 
Index to Allied and Nursing Health Literature (CINAHL), Google Scholar, Pub Med, 
Academic Search Premier, and the Cochrane Library. The keywords, phrases, and 
combinations used to acquire the results on these databases included neostigmine, 
sugammadex, sugammadex versus neostigmine, cost of sugammadex, cost of 
neostigmine, pharmaceutical pricing, group purchasing organizations, wholesale 
acquisition costs, and cost-efficiency. All literature included in this project was limited to 




NMBs can be divided into two broad categories which are depolarizing and 
nondepolarizing NMBs. Succinylcholine is a depolarizing NMB that acts on 
acetylcholine (ACh) receptors at the motor endplate causing depolarization of the cells 
(Nagelhout & Elisha, 2018). By depolarizing the cells, succinylcholine causes a 
prolonged refractory period in which muscle cannot be stimulated again until the resting 
membrane potential returns to normal (Nagelhout & Elisha, 2018). Succinylcholine still 
has its place among anesthesia providers because of its ultrashort action and is commonly 
used even though it is host to many potential adverse effects. However, succinylcholine’s 
mechanism of action and elimination differs from nondepolarizers. Succinylcholine does 
not require NMB reversal agents for the cessation of action. Therefore, succinylcholine’s 
relevance is limited in this report. 
Nondepolarizing NMBs are subdivided into benzylisoquinolines and steroidals. 
Benzylisoquinolines (atracurium, cisatracurium) act by binding to ACh receptors, 
thereby, inhibiting the ability of ACh to cause an action potential (Nagelhout & Elisha, 
2018). Inhibiting the action potential results in muscular relaxation. Benzylisoquinolines 
are degraded by physiologic temperature and pH, also known as Hoffman’s elimination. 
This class of NMBs is not antagonized by sugammadex, so its relevance is limited. 
Steroidals also act by binding to ACh receptors and blocking ACh, ultimately leading to 
muscle relaxation. Types of steroidals include rocuronium, vecuronium, and 
pancuronium. Each of these NMBs are eliminated by both renal and hepatic excretion 
(Nagelhout & Elisha, 2018). Rocuronium and vecuronium both fall into the intermediate-
acting group with a duration of action of 30-60 minutes. Pancuronium is a long-acting 
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NMB with a duration of action lasting 60-90 minutes. The effects of these NMBs are 
antagonized by anticholinesterases, such as neostigmine and edrophonium, which allows 
for greater quantities of ACh in the neuromuscular junction (Nagelhout & Elisha, 2018). 
The ACh then competes with the NMBs for ACh receptor binding. The effects of 
rocuronium and vecuronium can also be reversed with sugammadex.  
Train of four (TOF) ratios, tested with a nerve stimulator to cause four successive 
twitches, are often used by anesthesia practitioners to assess the depth of neuromuscular 
blockade. The response of the first twitch to the fourth twitch during nerve stimulation 
determines the designated ratio (Nagelhout & Elisha, 2018). Upon nerve stimulation prior 
to NMB administration, four equal twitch responses should be elicited. When 
nondepolarizing NMBs are administered, a dose-dependent decrease in muscle twitch 
response should be noted. TOF ratios during recovery from NMBs are then graded 
according to twitch response. TOF fade is noted when the strength of the contraction is 
weaker and weaker with each twitch. If the fourth twitch is visible but much weaker than 
the first twitch, the TOF ratio is likely less than 0.5 (Nagelhout & Elisha, 2018). If the 
fourth twitch is almost equal to the first twitch, the TOF is likely 0.9 or greater. 
Sugammadex 
Sugammadex (Bridion) is a selective NMB reversal agent that was approved by 
the FDA in 2015 (Cada et al., 2016). This medication is selective for steroidal NMBs, 
rendering it ineffective for use with benzylisoquinolines and succinylcholine. 
Sugammadex was originally designed to reverse the effects of rocuronium, but it has also 
been shown to counteract vecuronium as well (Cada et al., 2016).  
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Sugammadex is a y-cyclodextrin derivative that forms a 1:1 complex with 
rocuronium by encapsulating the molecule and inhibiting its ability to interact with ACh 
receptors (Cada et al., 2016; Carron et al., 2016; Ledowski et al., 2012). This method of 
NMB reversal differs from anticholinesterase/antimuscarinic combinations in that it 
works directly on the NMB molecule. Sugammadex’s sequestering of rocuronium causes 
a rapid onset of action with reliable reversal of steroidal neuromuscular blockade with a 
much lower incidence of residual postoperative paralysis, which can lead to harmful 
consequences (Ledowski et al., 2012).  
Sugammadex is supplied in 100 mg/ml concentrations in 2 ml and 5 ml vials. 
Current recommendations for reversal of rocuronium with sugammadex are based on 
TOF responses. Current recommendations state that sugammadex be given at doses of 2 
mg/kg for 2 twitches, 4 mg/kg for no twitches or a post-tetanic count (PTC) of 1 to 2, and 
16 mg/kg for emergency reversal (Cada et al., 2016; Nagelhout & Elisha, 2018). 
However, rocuronium reversal with as little as 0.5 mg/kg of sugammadex when a second 
twitch was observed has resulted in a 0.9 TOF ratio (Cada et al., 2016). 
TOF ratios used to assess effectiveness of aminosteroidal NMB reversal agents 
consistently showed a rapid return to a ratio of 0.9 or greater with sugammadex as 
compared to neostigmine (Abad-Gurumeta et al., 2015; Carron et al, 2016; Chambers et 
al. 2010; Ledowski et al., 2012; Unal et al., 2015). The difference in time to recovery of a 
TOF ratio of 0.9 or greater during a deep blockade with use of sugammadex as opposed 
to neostigmine is even greater. Cada et al. (2016) refer to a study in which reversal during 
a PTC of 1 to 2 resulted in a return to TOF ratio of 0.9 in 2.9 minutes with sugammadex 
in contrast to 50.4 minutes with neostigmine.  
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Although less adverse effects are associated with sugammadex, the y-cyclodextrin 
derivative has been speculated to be the cause of unanticipated consequences such as 
anaphylaxis, bradycardia, nausea, vomiting, and drug interactions (Cada et al., 2016; 
Nakanishi, Ishida, Utada, Yamaguchi, & Matsumoto, 2016). Nakanishi et al. (2016) 
report two previous positive hypersensitivity skin prick tests to sugammadex and one 
positive skin prick test they conducted themselves on a patient suspected to have 
hypersensitivity to the drug. During this study, diluted and undiluted concentrations of 
sugammadex alone and sugammadex mixed with rocuronium were administered via skin 
prick test. Their findings suggest that hypersensitivity is due to the amounts of free 
molecules of sugammadex and that sugammadex-rocuronium complexes that have been 
formed do not cause a reaction (Nakanishi et al., 2016). 
Drug interactions with sugammadex have also been noted. Toremifene, a drug 
used during breast cancer treatment, can bind to sugammadex because of its affinity for it 
which can delay NMB reversal (Cada et al., 2016). Sugammadex is thought to also bind 
to progesterone, which may render birth control ineffective. Ondansetron, ranitidine, and 
verapamil are physically incompatible to mix with sugammadex (Cada et al., 2016).  
As far as elimination, sugammadex binds with rocuronium and is excreted 
renally. The complex formed by rocuronium and sugammadex is eliminated unchanged. 
Therefore, sugammadex has been detected for up to 7 days when administered to patients 
with severe renal impairment (Cada et al, 2016).  
Neostigmine/Robinul 
Neostigmine, an anticholinesterase, and robinul, an antimuscarinic, have often 
been given in conjunction for reversal of NMBs. In contrast to sugammadex, reversal 
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with this combination can be used in benzylisoquinoline reversal or aminosteroidal 
reversal. Neostigmine’s anticholinesterase effects are primarily responsible for the 
reversal of NMBs because they inhibit the degradation of ACh by acetylcholinesterase 
(Nagelhout & Elisha, 2018). Robinul’s antimuscarinic effects are necessary to counteract 
side effects produced by the administration of neostigmine (Abad-Gurumeta et al., 2015; 
Nagelhout & Elisha, 2018). 
Neostigmine, when used as a reversal agent, forms a complex with 
acetylcholinesterase that inhibits the breakdown of ACh (Nagelhout & Elisha, 2018). A 
larger amount of ACh is then available in the neuromuscular junction to compete with 
NMBs for ACh receptor sites. The process ultimately leads to a greater possibility of 
eliciting an action potential. Because neostigmine does not directly act on 
nondepolarizing NMBs and depends on increased ACh to displace NMB molecules, the 
incidence of PORC is of greater concern (Abad-Gurumeta et al., 2015). If PORC is 
present after surgery, it can lead to atelectasis, pneumonia, respiratory failure, and 
possible re-intubation.  
When neostigmine is administered, side effects related to the inherent 
parasympathetic action of increased ACh will occur. The side effects include decreased 
heart rate, low blood pressure, postoperative nausea and vomiting (PONV), 
bronchoconstriction, hypersalivation, and arrhythmias (Nagelhout & Elisha, 2018). To 
offset these effects when administering neostigmine for NMB reversal, an antimuscarinic 
is given in conjunction with it. 
Robinul, an antimuscarinic, is usually given along with neostigmine for NMB 
reversal. Antimuscarinics are responsible for competitively blocking postganglionic 
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muscarinic receptors (Nagelhout & Elisha, 2018). Some types of these muscarinic 
receptors reside in cardiac and smooth muscle, which offsets the effects of increased ACh 
on organs innervated by parasympathetic nerves (Nagelhout & Elisha, 2018). Because 
skeletal muscle tissue is not innervated by these parasympathetic nerves, it is spared the 
antimuscarinic actions of robinul. Therefore, ACh continues to bind to ACh receptors on 
skeletal muscle tissue and reversing the NMBs, while it is also competitively blocked 
from binding to muscarinic receptors on cardiac and smooth muscle cells. This 
pharmacologic action attempts to reverse NMBs and avoid adverse events. 
Neostigmine is concentrated from 0.5 mg/ml to 1 mg/ml and robinul concentrated 
as 0.2 mg/ml. The recommended dose of robinul to neostigmine is 0.2 mg robinul to 1 
mg neostigmine (Nagelhout & Elisha, 2018). Neostigmine is supplied as 10 ml vials and 
robinul is supplied as 1 ml, 2 ml, 5 ml, and 20 ml vials. 
Pharmaceutical Pricing 
Drug pricing is a convoluted subject that greatly interferes with large scale 
estimations of cost across individual pharmacies and hospitals in the United States. Prices 
can vary greatly from one institution to another due to rebates, discounts, wholesaler 
purchasing, GPOs, and AWPs among other things (Mattingly, 2012). Therefore, one drug 
may cost a hospital a great deal more to supply and administer than another. 
The average manufacturer price (AMP) is the estimated price paid by a wholesaler or 
direct purchaser for a drug with rebates and discounts included. The wholesale 
acquisition cost (WAC) is the actual price of the drug that the manufacturer is selling 
without rebates or discounts included. Manufacturers offer rebates and discounts often, so 
the AMP is a better estimate after rebates and discounts are calculated (Mattingly, 2012). 
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Hospitals and pharmacies can purchase medications from a wholesaler for the 
average wholesale price (AWP) or from the manufacturer directly for the average 
manufacturer price (AMP) (Mattingly, 2012). However, the location of the manufacturer 
and supply of the medications directly impacts the ability of facilities to purchase directly 
from the manufacturers. Hospitals typically purchase drugs from wholesalers, but the 
price is usually marked up from the WAC or AMP by a certain percentage (Mattingly, 
2012). Wholesalers can also offer discounts and state Medicaid programs will reimburse 
pharmacies for carrying certain medications, which produces further variation in 
medication cost (Mattingly, 2012). 
With the steadily increasing costs of medications in the United States, GPOs have 
grown in number and size to improve buyer purchasing power (Graf, 2014). GPOs are 
made up of healthcare providers, hospitals, hospital staff, pharmacies, and other affiliates 
in which the supply of medication directly impacts their business (Dobson, Heath, 
Reuter, & DeVanzo, 2014). The GPOs negotiate with multiple wholesalers and 
manufacturers to establish the most competitive price to include rebates, discounts, and 
list price. In 2012, the savings estimated from GPOs for its members and consumers was 
around $22 billion and $55.2 billion (Dobson et al., 2014). Therefore, the formation and 
use of GPOs can decrease healthcare costs and increase consumer power (Dobson et al., 
2014; Graf, 2014).  
Summary 
The purpose of this project is to evaluate the cost of sugammadex versus 
neostigmine/robinul. The literature review reflects the benefits and risks of these 
medications and how they should be balanced with the cost that the facility is incurring 
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for their use. Benefits of sugammadex include rapid, reliable reversal of NMBs and lower 
incidence of PORC. On the other hand, sugammadex has been associated with rare, but 
serious, adverse effects. Neostigmine/robinul combination has traditionally been used for 
NMB reversal, so it is trusted by anesthesia providers. Rates of PORC and associated 
complications are higher with neostigmine/robinul, however. Limited information exists 
on the exact cost of these medications due to drug purchasing economics. However, 
estimating the cost at a single facility between the use of sugammadex and 




CHAPTER II – METHODOLOGY 
Target Outcome 
The target outcome of this study was to determine the cost-efficiency of full dose 
sugammadex in comparison with full dose neostigmine/robinul for NMB reversal. The 
cost analysis, in conjunction with a relevant literature review of risks and benefits of the 
medications, was meant to guide the selection of these NMB reversal agents in clinical 
practice. The long-term goal was cost savings and safe, quality healthcare. To insert an 
additional chapter(s) in this template follow these steps: 
Population and Setting 
The population included any operations for patients requiring NMBs. The setting 
was at a hospital in North Mississippi. This hospital has a 9-bed OR that is responsible 
for performing arthroscopic, endoscopic, orthopedic, cardiovascular, and general surgery 
cases. 
Design 
The medication costs for a full dose reversal with sugammadex alone and 
neostigmine/robinul combination were collected and analyzed. The data was compiled 
into an excel spreadsheet to illustrate and organize the costs accrued for comparison. 
Findings were then communicated with the CRNAs at the hospital. 
Barriers 
A barrier present in this analysis is the variation of costs associated with these 
drugs. The price of these drugs is subject to variability among not only other hospitals, 
but within the hospital, the study occurred in as well. No variations in price occurred 
during data collection in this project, however. Research data of cost-related material in 
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regard to sugammadex versus neostigmine/robinul was also limited. The FDA approved 
sugammadex in 2015, so information regarding its cost is limited. 
Methodology 
The chief CRNA provided a letter of approval from the hospital and The 
University of Southern Mississippi Institutional Review Board (IRB) also approved the 
project (IRB-19-88, Appendix B). The hospital pharmacy was then contacted to obtain 
information related to the expenses of sugammadex, neostigmine, and robinul. 
Information regarding the quantity of cases for the 6 months prior to project 
implementation, requiring NMBs and subsequent NMB reversal agents, was gathered 
from the chief CRNA. An average number of cases was calculated per month. The full 
dose reversal cost of sugammadex was applied to the average monthly caseload to 
determine the estimated expense for the month. The full dose reversal cost of 
neostigmine/robinul was also applied to the average monthly cases to estimate the 
monthly expenditure. The estimated monthly expense for both NMB reversal agents was 
then projected over a 6-month period to identify the estimated cost difference over time 
based on average monthly case numbers. All information was placed in excel format. The 
costs were compared and analyzed with an estimated difference calculated. A cost-
efficiency analysis report was written and prepared for review. The report was reviewed 
by a panel of experts before presenting the results to anesthesia staff at the hospital where 
this project was conducted. A recommendation based off of the report for selection of an 
NMB reversal agent for cases requiring NMB was given to the chief CRNA. This 
information was stored in a password-protected computer for a 6-month period following 




This project identified the cost efficiency of sugammadex versus 
neostigmine/robinul and provided enlightenment regarding the known risks and benefits 
of each. The data was gathered, quantified, and analyzed for presentation. The project 
was conducted at a hospital with a 9-bed OR. Approval was received from both the 






CHAPTER III  - RESULTS 
Analysis 
Purchasing information for neostigmine, robinul, and sugammadex was obtained 
from the pharmacy. The prices were represented as cost per vial, and the concentrations 
of the NMB reversal agents were also provided. Prices and concentrations for the 
medications are listed in Table 1. 
Table 1  
Cost of NMB Reversals by Vial 
Medication Concentration Cost per vial 
Sugammadex 100mg/mL, 2mL $94.37 
Neostigmine 1mg/mL, 10mL $5.95 
Robinul 0.2mg/mL, 2mL $4.21 
 
The hospital belongs to a GPO and purchases its medications almost exclusively 
through a wholesaler. The hospital is also a disproportionate share hospital (DSH), which 
enables it to receive special pricing on the robinul along with a 2.5% rebate through the 
GPO. The sugammadex and neostigmine are only subject to GPO contract pricing with 
no included rebates or discounts.  
Average case numbers requiring NMB reversals per month were calculated by 
using billing information retrieved from the pharmacy and chief CRNA. All cases that 
involved NMB reversals from January 1, 2019, to June 30, 2019, were included during 
this calculation. The information was recorded in excel format and can be viewed in 
Table 2.  
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Table 2  
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The cost of neostigmine/robinul combination versus sugammadex alone was then 
applied to the average case number per month to yield the final results. The 200 mg 
single-dose vial of sugammadex was applied to the 112 cases as the vial contains an 
average full dose reversal. The maximum full dose reversal of neostigmine is 5 mg given 
concomitantly with 1 mg of robinul (Nagelhout & Elisha, 2018). The neostigmine 
available at the hospital is multidose vials with the concentration supplied as 10 mg per 
vial. However, even multidose vials should be dedicated to single patient use when in a 
patient treatment area, such as the OR. Therefore, the cost of 1 vial of neostigmine and 3 
vials of robinul were used for a single reversal dose and applied to the 112 cases. The 
data was compiled into an excel spreadsheet and can be seen in Table 3. 
Table 3  
Cost of Neostigmine/Robinul Combination Versus Sugammadex at 1 Month and 6 Months 








Sugammadex 1 Vial $94.37 112 $10,569.44 $63,416.64 
Neostigmine/Robinul 1 Vial/3 
Vials 
$18.58 112 $2,080.96 $12,485.76 
 
Results 
The costs were calculated for both neostigmine/robinul combination and 
sugammadex, then projected over a 6-month period. The results were analyzed and 
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compared to show that neostigmine/robinul combination is the more cost-efficient option. 
As Table 3 shows, the cost of sugammadex at the end of the 6 months shows a total of 
$63,416.64, as compared to $12,485.76 for neostigmine/robinul combination. This totals 
out for a difference of $50,930.88, which results in 80.3% costs-savings. Variables 
specific to this hospital regarding pricing and drug usage may not apply to other facilities. 
These variables will be discussed as limitations to this study in the next chapter. 
Summary 
The project purpose was to establish the cost difference between 
neostigmine/robinul combination and sugammadex for reversing NMB. Based upon 
pricing information received from the facility’s pharmacy and subsequent evaluation of 
the results, the neostigmine/robinul combination was the more cost-efficient choice. The 
results were then communicated to the chief CRNA and anesthesia staff at the hospital, 




CHAPTER IV – DISCUSSION 
Presentation of Results to Anesthesia Providers 
The results were disseminated to anesthesia staff at the facility. Six of the CRNAs 
at the facility voluntarily participated in the panel of experts questionnaire after reviewing 
the results. The questionnaire can be viewed in Appendix C. All respondents agreed that 
the presentation of results adequately reflected the cost evaluation of sugammadex and 
neostigmine/robinul. All respondents also agreed that they were not encouraged to select 
an alternative reversal agent based on the information provided. Therefore, they did not 
consider a practice change to sugammadex alone over neostigmine/robinul. Some of the 
anesthesia providers did state in the comments section that sugammadex would be a good 
alternative to prevent complications of residual paralysis when neostigmine/robinul 
combination was not adequate. In an effort to minimize cost, the CRNAs could give 
sugammadex to completely reverse NMB after neostigmine/robinul had already been 
given. 
Limitations 
Many limitations exist in terms of extrapolating the data from this project to 
another facility. Rebates, discounts, reimbursement, price negotiating organizations, and 
other factors specific to other healthcare institutions can affect the pricing of each drug. 
Some anesthesia providers at the facility the project was conducted in may choose to use 
half doses of neostigmine/robinul for reversal. Although using half doses would not 
affect neostigmine use per vial, only one or two robinul vials may be used. Another 
potential limitation to this project is the anesthesia providers’ concomitant use of 
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sugammadex when neostigmine/robinul reversal is inadequate which would further alter 
results. 
Future Implications 
Projects executed at this facility in the future related to cost efficiency of 
sugammadex versus neostigmine/robinul should prioritize units of OR time, recovery 
room time, and postoperative complications. Evaluating units of OR time, recovery room 
time, and postoperative complications would expand the amount of cost-related data that 
could be collected. Cost to the patient cost to the hospital and efficacy of the drugs in 
preventing complications could be assessed. Preventing complications during the 
postoperative period would also decrease cost by avoiding use of other medical supplies 
needed during intervention. 
Discussion 
The chief CRNA at a hospital in North Mississippi contacted this DNP student to 
compare the cost of sugammadex versus neostigmine/robinul combination for NMB 
reversal. This DNP student accepted the proposal. An extensive literature review related 
to the cost of these NMB reversal agents was performed. The pharmacy was contacted 
regarding the pricing of the NMB reversal agents. The costs were applied to the mean 
number of general anesthetic cases requiring NMB reversal per month and then extended 
over the course of 6 months. All information was placed in excel format. A difference of 
$50,930.88 at the end of a 6-month period was calculated in favor of neostigmine/robinul. 
The difference results in 80.3% cost-savings for the facility. Neostigmine/robinul 
combination, when compared to sugammadex by cost analysis, appears to be the more 




The literature review and cost analysis indicate an imbalance between medication 
efficiency and cost. At the hospital, the project was conducted, neostigmine/robinul is 
much more cost-efficient for NMB reversal. However, recent research would suggest that 
avoiding complications and decreasing OR time with sugammadex will also aid in 
avoiding unnecessary costs. Therefore, this DNP student recommends continuing the use 
of neostigmine/robinul due to the lower cost of these medications at the facility the 
project was conducted. If there is inadequate reversal of NMB with neostigmine/robinul 
combination, then it would be prudent to administer sugammadex to avoid postoperative 
complications and increased hospital time. This DNP student would also recommend 
investigation into the cost of OR time, recovery room time, and postoperative 





APPENDIX A – DNP Essentials 
Table A1.  
DNP Essentials 
Essential I Scientific Underpinnings 
for Practice 
Performed a literature 
review of the cost, benefits, 
and risks of both 
sugammadex and 
neostigmine/robinul. 
Essential II Organizational and Systems 
Leadership for Quality 
Improvement and Systems 
Thinking 
Established the cost 
efficiency of full dose 
reversal of NMB with 
sugammadex versus 
neostigmine/robinul and 
presenting evidence of the 
benefits and risks of each. 
Essential III Clinical Scholarship and 
Analytical Methods for 
Evidence-Based Practice 
Applied information 
gathered from the literature 
review and created an 
analyzed cost comparison 
between NMB reversal 
agents. 
Essential IV Information 
Systems/Technology and 
Patient Care Technology for 
the Improvement of 
Transformation of Health 
Care 
Conducted a literature 
review by using information 
databases and by accessing 
hospital resources for cost 
estimation. 
Essential V Health Care Policy for 
Advocacy in Health Care 
Formed results and 
presented the results to 
anesthesia staff at the health 
care facility to improve 
health care delivery. 
Essential VI Inter-professional 
Collaboration for Improving 
Patient and Population 
Health Outcomes 
Interacted with anesthesia 
staff at the healthcare 
facility regarding cost 
efficiency of NMB reversal 
selection and known risks 
and benefits of each type. 
Essential VII Clinical Prevention and 
Population Health for 
Improving the Nation’s 
Health 
Reviewed current literature 
regarding the benefits and 
risks of NMB agents as it 
relates to cost efficiency so 
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safe, quality health care 
delivery can be given. 
Essential VIII Advanced Nursing Practice Presented results of the cost 
efficiency analysis of 
sugammadex versus 
neostigmine/robinul to the 
CRNAs with respect to the 
benefits and risks provided 











APPENDIX C – Panel of Experts of Questionnaire 
Evaluation Tool 
Participation in this anonymous questionnaire is voluntary. There are no repercussions for 
nonparticipation. Thank you for your time. 
Please answer the following questions with a yes or no response. 
1) Did this project presentation provide you with information regarding cost evaluation 
between sugammadex and neostigmine/robinul reversal agents for patients 
undergoing general anesthesia? 
a. Yes 
b. No 
2) Did the information provided in this presentation encourage you to reconsider your 
current selection of reversal agents? 
a. Yes 
b. No 
3) Would you consider changing your practice based on the information presented if 
given the option to provide sugammadex? 
a. Yes 
b. No 
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